StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$129.36−6.32 (-4.66%)

Close on Nov 20, 2026Market cap $6.78BP/E –Yield –

Axsome Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Axsome Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$186.07M. For fiscal 2025 it was -$166.76M. The highest annual figure on record is -$5.67M in fiscal 2014.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$166.76M–
FY2024Dec 31, 2024-$280.56M–
FY2023Dec 31, 2023-$231.83M–
FY2022Dec 31, 2022-$179.80M–
FY2021Dec 31, 2021-$124.71M–
FY2020Dec 31, 2020-$99.14M–
FY2019Dec 31, 2019-$67.25M–
FY2018Dec 31, 2018-$32.85M–
FY2017Dec 31, 2017-$27.16M–
FY2016Dec 31, 2016-$27.54M–
FY2015Dec 31, 2015-$9.20M–
FY2014Dec 31, 2014-$5.67M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$49.65M–
Q1 FY2026Mar 31, 2026-$63.36M–
Q4 FY2025Dec 31, 2025-$26.96M–
Q3 FY2025Sep 30, 2025-$46.11M–
Q2 FY2025Jun 30, 2025-$36.71M–
Q1 FY2025Mar 31, 2025-$56.98M–
Q4 FY2024Dec 31, 2024-$72.62M–
Q3 FY2024Sep 30, 2024-$62.62M–
Q2 FY2024Jun 30, 2024-$78.05M–
Q1 FY2024Mar 31, 2024-$67.28M–
Q4 FY2023Dec 31, 2023-$98.27M–
Q3 FY2023Sep 30, 2023-$62.12M–
Q2 FY2023Jun 30, 2023-$65.06M–
Q1 FY2023Mar 31, 2023-$6.37M–
Q4 FY2022Dec 31, 2022-$59.92M–
Q3 FY2022Sep 30, 2022-$42.41M–
Q2 FY2022Jun 30, 2022-$39.18M–
Q1 FY2022Mar 31, 2022-$38.29M–
Q4 FY2021Dec 31, 2021-$32.61M–
Q3 FY2021Sep 30, 2021-$33.41M–
Q2 FY2021Jun 30, 2021-$30.85M–
Q1 FY2021Mar 31, 2021-$27.84M–
Q4 FY2020Dec 31, 2020-$27.74M–
Q3 FY2020Sep 30, 2020-$21.13M–
Q2 FY2020Jun 30, 2020-$17.78M–
Q1 FY2020Mar 31, 2020-$32.49M–
Q4 FY2019Dec 31, 2019-$24.43M-358.5%
Q3 FY2019Sep 30, 2019-$18.95M–
Q2 FY2019Jun 30, 2019-$13.45M–
Q1 FY2019Mar 31, 2019-$10.42M–
Q4 FY2018Dec 31, 2018$9.45M+46.7%
Q3 FY2018Sep 30, 2018-$8.24M-230.9%
Q2 FY2018Jun 30, 2018-$7.99M-218.4%
Q1 FY2018Mar 31, 2018-$7.16M-193.4%
Q4 FY2017Dec 31, 2017$6.44M-15.5%
Q3 FY2017Sep 30, 2017$6.30M-12.6%
Q2 FY2017Jun 30, 2017$6.75M–
Q1 FY2017Mar 31, 2017$7.67M–
Q4 FY2016Dec 31, 2016$7.63M–
Q3 FY2016Sep 30, 2016$7.21M–

More Axsome Therapeutics figures

See a number that looks wrong?